HRP20210350T1 - Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori plazmatskog kalikreina - Google Patents

Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori plazmatskog kalikreina Download PDF

Info

Publication number
HRP20210350T1
HRP20210350T1 HRP20210350TT HRP20210350T HRP20210350T1 HR P20210350 T1 HRP20210350 T1 HR P20210350T1 HR P20210350T T HRP20210350T T HR P20210350TT HR P20210350 T HRP20210350 T HR P20210350T HR P20210350 T1 HRP20210350 T1 HR P20210350T1
Authority
HR
Croatia
Prior art keywords
plasma kallikrein
disease
arylmethyl
het
heteroaryl
Prior art date
Application number
HRP20210350TT
Other languages
English (en)
Inventor
Rebecca Louise DAVIE
Hannah Joy EDWARDS
David Michael Evans
Simon Teanby Hodgson
Original Assignee
Kalvista Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52349552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20210350(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kalvista Pharmaceuticals Limited filed Critical Kalvista Pharmaceuticals Limited
Publication of HRP20210350T1 publication Critical patent/HRP20210350T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (1)

1. Spoj Formule (I), ili njegova farmaceutski prihvatljiva sol ili solvat za upotrebu u postupku liječenja bolesti ili stanja u koja je uključena aktivnost plazmatskog kalikreina, gdje bolest ili stanje u koje je uključena aktivnost plazmatskog kalikreina je izabrana između oštećene oštrine vida, dijabetičke retinopatije, dijabetičkog makularnog edema, nasljednog angioedema, dijabetesa, upale gušterače, cerebralnog krvarenja, nefropatije, kardiomiopatije, neuropatije, upalne bolesti crijeva, artritisa, upale, septičkog šoka, niskog krvnog tlaka, raka, respiratornog distres sindroma kod odraslih, diseminirane intravaskularne koagulacije, operacija kardiopulmonarne premosnice i postoperativnog krvarenja, pri čemu je spoj Formule (I) : [image]
HRP20210350TT 2014-11-27 2021-03-01 Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori plazmatskog kalikreina HRP20210350T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1421083.5A GB201421083D0 (en) 2014-11-27 2014-11-27 Enzyme inhibitors
EP19182383.0A EP3567037B1 (en) 2014-11-27 2015-11-26 N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

Publications (1)

Publication Number Publication Date
HRP20210350T1 true HRP20210350T1 (hr) 2021-04-16

Family

ID=52349552

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20220314TT HRP20220314T1 (hr) 2014-11-27 2015-11-26 Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao plazma kallikrein inhibitori
HRP20191524 HRP20191524T1 (hr) 2014-11-27 2019-08-23 Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori kalikreina plazme
HRP20210350TT HRP20210350T1 (hr) 2014-11-27 2021-03-01 Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori plazmatskog kalikreina

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HRP20220314TT HRP20220314T1 (hr) 2014-11-27 2015-11-26 Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao plazma kallikrein inhibitori
HRP20191524 HRP20191524T1 (hr) 2014-11-27 2019-08-23 Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori kalikreina plazme

Country Status (37)

Country Link
US (6) US10364238B2 (hr)
EP (4) EP3224256B1 (hr)
JP (4) JP6653702B2 (hr)
KR (2) KR102496404B1 (hr)
CN (2) CN110577519A (hr)
AR (2) AR102850A1 (hr)
AU (2) AU2015352193B2 (hr)
BR (1) BR112017010882B8 (hr)
CA (1) CA2967894C (hr)
CL (1) CL2017001362A1 (hr)
CO (1) CO2017006230A2 (hr)
CY (3) CY1122255T1 (hr)
DK (3) DK3224256T3 (hr)
EC (1) ECSP17039127A (hr)
ES (3) ES2908303T3 (hr)
GB (1) GB201421083D0 (hr)
HK (1) HK1244268A1 (hr)
HR (3) HRP20220314T1 (hr)
HU (3) HUE053317T2 (hr)
IL (2) IL278182B (hr)
LT (3) LT3567037T (hr)
MA (3) MA41014B1 (hr)
MD (3) MD3224256T2 (hr)
ME (1) ME03514B (hr)
MX (2) MX2017006823A (hr)
MY (1) MY176853A (hr)
NZ (1) NZ731945A (hr)
PH (1) PH12017500901A1 (hr)
PL (3) PL3556752T3 (hr)
PT (3) PT3224256T (hr)
RS (3) RS63155B1 (hr)
RU (2) RU2707870C2 (hr)
SG (2) SG10201907819WA (hr)
SI (3) SI3567037T1 (hr)
TW (2) TWI741377B (hr)
UA (1) UA123087C2 (hr)
WO (1) WO2016083820A1 (hr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
TWI734702B (zh) 2015-10-01 2021-08-01 美商百歐克斯製藥公司 人類血漿激肽釋放酶抑制劑
GB201609519D0 (en) * 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
SI3464271T1 (sl) * 2016-05-31 2020-10-30 Kalvista Pharmaceuticals Limited Derivati pirazola kot inhibitorji plazemskega kalikreina
GB201609607D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
WO2018200674A1 (en) * 2017-04-26 2018-11-01 Mitobridge, Inc. Dynamin-1-like protein inhibitors
TW201925188A (zh) * 2017-11-29 2019-07-01 英商卡爾維斯塔製藥有限公司 酶抑制劑
DK3716952T3 (da) 2017-11-29 2022-03-14 Kalvista Pharmaceuticals Ltd Doseringsformer omfattende en plasmakallikrein-inhibitor
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201719882D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
EP3765459A1 (en) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN114728962A (zh) 2019-09-18 2022-07-08 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
WO2021121396A1 (zh) * 2019-12-20 2021-06-24 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的三环类化合物及其用途
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2021175290A1 (zh) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 杂环类化合物
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
EP4232031A1 (en) 2020-10-23 2023-08-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (ja) 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023185634A1 (zh) * 2022-03-30 2023-10-05 南京明德新药研发有限公司 作为血浆激肽释放酶抑制剂的杂环类化合物
EP4288036A1 (en) 2022-04-27 2023-12-13 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
WO2024025907A1 (en) * 2022-07-29 2024-02-01 Rezolute, Inc. Inhibitors of plasma kallikrein

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US7101878B1 (en) 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
IL144910A0 (en) * 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
EP1451160B1 (en) 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides for use in the treatment of pain
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
ES2298513T3 (es) 2002-04-26 2008-05-16 Eli Lilly And Company Derivados de tiazol como antagonistas del receptor de taquicinina.
EP1426364A1 (en) 2002-12-04 2004-06-09 Aventis Pharma Deutschland GmbH Imidazole-derivatives as factor Xa inhibitors
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
TW200505450A (en) 2003-02-03 2005-02-16 Janssen Pharmaceutica Nv Quinoline-derived amide modulators of vanilloid VR1 receptor
JP4951339B2 (ja) 2003-08-27 2012-06-13 オプソテツク・コーポレイシヨン 眼血管新生疾患の治療のための併用療法
TW200526588A (en) * 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
BRPI0514843A (pt) 2004-09-03 2008-06-24 Yuhan Corp derivados de pirrolo[3,2-c] piridina e processos para a preparação dos mesmos
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
WO2007011328A1 (en) 2005-07-14 2007-01-25 Jackson Kenneth A A method for disabling a hypodermic needle after use
AU2006270322A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
GB0606876D0 (en) * 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
US20070258976A1 (en) 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
SI2049478T1 (sl) 2006-07-06 2012-08-31 Glaxo Group Ltd Substituirani N-fenilmetil-5-okso-prolin-2-amidi kot antagonisti receptorja P2X7 in postopki za njihovo uporabo
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
BRPI0721298A2 (pt) 2006-12-29 2014-03-25 Abbott Gmbh & Co Kg Composto de carboxamida e seus usos como inibidores de calpaína
US20100119512A1 (en) 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US20080221093A1 (en) 2007-03-07 2008-09-11 Christian Gege Metalloprotease inhibitors containing a heterocyclic moiety
MX2009009443A (es) 2007-03-30 2009-09-14 Sanofi Aventis Compuestos de pirimidina hidrazida como inhibidores de pgds.
JP2010523524A (ja) 2007-04-03 2010-07-15 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのイミダゾリジンカルボキサミド誘導体
RU2010106393A (ru) 2007-07-26 2011-09-10 Зингента Партисипейшнс Аг (Ch) Новые микробиоциды
JP2010536871A (ja) 2007-08-22 2010-12-02 アラーガン、インコーポレイテッド スフィンゴシン−１−リン酸受容体アゴニストまたはアンタゴニスト生物学的活性を有するピロール化合物
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009083553A1 (en) 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
US8658685B2 (en) 2008-01-31 2014-02-25 Activesite Pharmaceuticals, Inc. Methods for treatment of kallikrein-related disorders
WO2009106980A2 (en) 2008-02-29 2009-09-03 Pfizer Inc. Indazole derivatives
JP5537442B2 (ja) 2008-03-13 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー 第ｘｉａ因子阻害剤としてのピリダジン誘導体
CN102149680B (zh) 2008-07-08 2014-12-10 第一三共株式会社 含氮芳族杂环化合物
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
MX2012006913A (es) 2009-12-18 2012-08-23 Activesite Pharmaceuticals Inc Profarmacos de inhibidores de calicreina plasmatica.
JP2011157349A (ja) 2010-01-07 2011-08-18 Daiichi Sankyo Co Ltd 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物
ES2569983T3 (es) 2010-01-28 2016-05-13 The Medicines Company (Leipzig) Gmbh Inhibidores de serinproteasa de tipo tripsina y su preparación y uso
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
EP2458315B1 (de) 2010-11-25 2017-01-04 Balcke-Dürr GmbH Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9133128B2 (en) 2011-06-17 2015-09-15 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
US8952180B2 (en) 2011-09-27 2015-02-10 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9249096B2 (en) 2011-09-27 2016-02-02 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013111108A1 (en) * 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
AU2013216721B2 (en) 2012-02-10 2017-09-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013130603A1 (en) 2012-02-27 2013-09-06 Board Of Regents, The University Of Texas System Ganglioside gd2 as a marker and target on cancer stem cells
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
CN104918942A (zh) 2013-01-08 2015-09-16 萨维拉制药有限公司 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途
GB201300304D0 (en) * 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
CA2897336C (en) 2013-01-20 2023-10-17 Dyax Corp. Evaluation and treatment of pkal-mediated disorders
EP2968297B1 (en) 2013-03-15 2018-09-26 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
AU2014270152B9 (en) 2013-05-23 2018-03-08 Kalvista Pharmaceuticals Limited Heterocyclic derivates
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
CA2920815C (en) 2013-08-14 2021-09-21 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CN106061480B (zh) 2013-12-30 2020-02-28 莱福斯希医药公司 治疗性抑制性化合物
LT3828173T (lt) 2014-03-07 2022-11-10 Biocryst Pharmaceuticals, Inc. Pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
WO2015171526A2 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Tricyclic pyrazolopyridine compounds
WO2015171527A1 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
BR112017000816A2 (pt) 2014-07-16 2017-12-05 Lifesci Pharmaceuticals Inc compostos inibitórios terapêuticos
WO2016029214A1 (en) 2014-08-22 2016-02-25 Biocryst Pharmaceuticals, Inc. Compositions and uses of amidine derivatives
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
HUE060104T2 (hu) 2015-02-27 2023-01-28 Verseon Int Corporation Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok
EP3317241A4 (en) 2015-07-01 2019-01-23 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS
EP3317259A4 (en) 2015-07-01 2019-06-12 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITING COMPOUNDS
EP3368529B1 (en) 2015-10-27 2022-04-06 Boehringer Ingelheim International GmbH Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
US10640486B2 (en) 2015-10-27 2020-05-05 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
GB201609519D0 (en) 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
SI3464271T1 (sl) 2016-05-31 2020-10-30 Kalvista Pharmaceuticals Limited Derivati pirazola kot inhibitorji plazemskega kalikreina
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
GB201719882D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
TW201925188A (zh) 2017-11-29 2019-07-01 英商卡爾維斯塔製藥有限公司 酶抑制劑
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof

Also Published As

Publication number Publication date
EP4039681A1 (en) 2022-08-10
CN110577519A (zh) 2019-12-17
JP7148683B2 (ja) 2022-10-05
LT3556752T (lt) 2022-03-10
CO2017006230A2 (es) 2017-09-11
KR20170090451A (ko) 2017-08-07
HUE047425T2 (hu) 2020-04-28
RU2707870C2 (ru) 2019-12-02
US20190330200A1 (en) 2019-10-31
MX2020013038A (es) 2022-12-09
LT3567037T (lt) 2021-02-25
US20200199116A1 (en) 2020-06-25
RU2017122364A3 (hr) 2019-06-19
JP2020033357A (ja) 2020-03-05
PT3556752T (pt) 2022-04-14
IL278182B (en) 2022-09-01
MD3224256T2 (ro) 2019-12-31
MA41014A (fr) 2017-10-04
AU2019240616B2 (en) 2021-07-29
HUE053317T2 (hu) 2021-06-28
UA123087C2 (uk) 2021-02-17
MA41014B1 (fr) 2019-09-30
US10611758B2 (en) 2020-04-07
SG11201703988PA (en) 2017-06-29
CN107108576A (zh) 2017-08-29
PL3556752T3 (pl) 2022-05-02
JP6995101B2 (ja) 2022-01-14
MA52063B1 (fr) 2022-01-31
PL3224256T3 (pl) 2020-01-31
TWI741377B (zh) 2021-10-01
JP2022180520A (ja) 2022-12-06
TW202026285A (zh) 2020-07-16
SI3224256T1 (sl) 2019-12-31
PH12017500901A1 (en) 2017-12-18
BR112017010882A2 (pt) 2017-12-26
CN107108576B (zh) 2020-03-10
MX2017006823A (es) 2017-09-27
MA47217A (fr) 2019-11-13
IL278182A (en) 2020-11-30
SG10201907819WA (en) 2019-09-27
PT3224256T (pt) 2019-09-23
EP3556752B1 (en) 2022-01-05
US11198691B2 (en) 2021-12-14
IL252287A0 (en) 2017-07-31
TW201625548A (zh) 2016-07-16
AR121273A2 (es) 2022-05-04
SI3556752T1 (sl) 2022-05-31
BR112017010882B1 (pt) 2023-10-31
NZ770256A (en) 2021-11-26
CA2967894A1 (en) 2016-06-02
MA52063A (fr) 2021-05-26
US11084809B2 (en) 2021-08-10
AU2015352193B2 (en) 2019-10-10
BR112017010882B8 (pt) 2023-10-31
KR20210075227A (ko) 2021-06-22
GB201421083D0 (en) 2015-01-14
EP3224256B1 (en) 2019-07-03
DK3224256T3 (da) 2019-09-23
LT3224256T (lt) 2019-09-25
EP3567037A1 (en) 2019-11-13
MD3556752T2 (ro) 2022-07-31
ME03514B (me) 2020-04-20
ES2908303T3 (es) 2022-04-28
IL252287B (en) 2020-11-30
US20190300517A1 (en) 2019-10-03
MY176853A (en) 2020-08-24
KR102496404B1 (ko) 2023-02-06
US20200361923A1 (en) 2020-11-19
RS59395B1 (sr) 2019-11-29
RS63155B1 (sr) 2022-05-31
CY1125214T1 (el) 2023-06-09
US20180319782A1 (en) 2018-11-08
US20220289729A1 (en) 2022-09-15
HUE057647T2 (hu) 2022-05-28
CA2967894C (en) 2024-01-30
RS61497B1 (sr) 2021-03-31
DK3556752T3 (da) 2022-03-07
CY1124046T1 (el) 2022-05-27
US10364238B2 (en) 2019-07-30
JP2021185138A (ja) 2021-12-09
MD3567037T2 (ro) 2021-05-31
CL2017001362A1 (es) 2018-02-09
ES2745815T3 (es) 2020-03-03
AU2015352193A1 (en) 2017-06-08
PT3567037T (pt) 2021-02-23
WO2016083820A1 (en) 2016-06-02
ES2858082T3 (es) 2021-09-29
KR102267623B1 (ko) 2021-06-18
EP3556752A1 (en) 2019-10-23
RU2019131174A (ru) 2019-10-10
HRP20191524T1 (hr) 2019-11-29
CY1122255T1 (el) 2020-11-25
EP3567037B1 (en) 2020-12-23
HRP20220314T1 (hr) 2022-05-13
AR102850A1 (es) 2017-03-29
RU2017122364A (ru) 2018-12-27
HK1244268A1 (zh) 2018-08-03
MA47217B1 (fr) 2021-04-30
ECSP17039127A (es) 2017-12-01
EP3224256A1 (en) 2017-10-04
NZ731945A (en) 2021-07-30
TWI686383B (zh) 2020-03-01
US11001578B2 (en) 2021-05-11
JP2017535568A (ja) 2017-11-30
DK3567037T3 (da) 2021-02-08
SI3567037T1 (sl) 2021-04-30
PL3567037T3 (pl) 2021-06-14
JP6653702B2 (ja) 2020-02-26
AU2019240616A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
HRP20210350T1 (hr) Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori plazmatskog kalikreina
HRP20201131T1 (hr) Derivati pirazola kao inhibitori kalikreina plazme
JP2019517464A5 (hr)
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
HRP20201916T1 (hr) Trifluorometil supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
CR20160035A (es) Inhibidores de bromodominios
PH12016502581A1 (en) TrK-INHIBITING COMPOUND
CL2015003442A1 (es) Derivados heterociclicos
CA2897273C (en) Benzylamine derivatives
MX2015010971A (es) Derivado novedoso de pirazol.
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
MX2017004129A (es) Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2- il)amino-benzoico como inhibidor de quinasa p38.
UY35395A (es) Inhibidores de bromodominios tetracíclicos
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
TR201908994T4 (tr) Farmasötik bileşimler.
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
ME03016B (me) Derivat piridina
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
GEP20207095B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
MX2017008495A (es) Nuevos derivados de bencimidazol como agentes antihistaminicos.
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
SI2999707T1 (en) Tylosin derivatives and their preparation process
PH12015501555A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
WO2016165205A8 (zh) 一种新型的bcr-abl激酶抑制剂